ADC Therapeutics to Host Third Quarter 2020 Financial Results Conference Call on

Therapeutics to Host Third Quarter 2020

Results Conference Call on November 12, 2020

Switzerland, November 5, 2020 - ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology

company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients

with hematological malignancies and solid tumors, today announced that it will host a conference call and live webcast on Thursday,

November 12, 2020 at 8:30 am ET to report financial results for the third quarter ended September 30, 2020 and provide business

access the live call, please dial 833-249-8403 (domestic) or +

41 225675632 (international). A live webcast of the presentation will be available under "Events and Presentations"

on the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com. The archived webcast will be available after

the completion of the event and for 30 days following the call.

Therapeutics SA (NYSE:ADCT) is a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization

of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors. The

Company develops ADCs by applying its decades of experience in this field and using next-generation pyrrolobenzodiazepine (PBD)

technology to which ADC Therapeutics has proprietary rights for its targets. Strategic target selection for PBD-based ADCs and

substantial investment in early clinical development have enabled ADC Therapeutics to build a deep clinical and research pipeline

of therapies for the treatment of hematological and solid tumor cancers. The Company has multiple PBD-based ADCs in ongoing clinical

trials, ranging from first in human to confirmatory Phase 3 clinical trials, in the USA and Europe, and numerous preclinical ADCs

tesirine (Lonca, formerly ADCT-402), the Company's lead product candidate, has been evaluated in a 145-patient pivotal Phase

2 clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that showed a 48.3% overall

response rate (ORR), which exceeded the target primary endpoint. In September 2020, ADC Therapeutics submitted a Biologics License

Application to the U.S. Food and Drug Administration seeking accelerated approval for Lonca for the treatment of patients with

relapsed or refractory DLBCL. Camidanlumab tesirine (Cami, formerly ADCT-301), the Company's second lead product candidate,

is being evaluated in a 100-patient pivotal Phase 2 clinical trial for the treatment of relapsed or refractory Hodgkin lymphoma

(HL) after having shown in a Phase 1 clinical trial an 86.5% ORR in HL patients at the dose selected for Phase 2. The Company

is also evaluating Cami as a novel immuno-oncology approach for the treatment of various advanced solid tumors.

Therapeutics is based in Lausanne (Biop le), Switzerland and has operations in London, the San Francisco Bay Area and New

Jersey. For more information, please visit.https://adctherapeutics.com/ and

follow the Company on Twitter and LinkedIn.

Tel.: +1 917 288 7023

Tel: +41 (0) 43 268 3231

Tel.: +1 973-415-8838